http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022133089-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8a1d7944b67b5f9747e99ebf1c001f13
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-4611
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-4631
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
filingDate 2021-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ada25384b333a3d9c3cf7cf46c69e3ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d963aef5d491e655c5deeb3857f2da3c
publicationDate 2022-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2022133089-A1
titleOfInvention Cea6 binding molecules and uses thereof
abstract Disclosed herein are carcinoembryonic antigen 6 (CEA6)-specific binding polypeptides. These binding polypeptides may be incorporated into chimeric antigen receptors (CARs). Also disclosed herein are methods of using these binding polypeptides and/or CARs for the treatment of, for example, a cancer.
priorityDate 2020-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010022452-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005053608-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019178316-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019126399-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011177095-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020181261-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60961
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393686
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5366546
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409442

Total number of triples: 39.